Caris Life Sciences, Inc.
CAI
$18.24
-$0.23-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -68.09M | -186.99M | -279.05M | -273.44M | -281.89M |
| Total Depreciation and Amortization | 22.62M | 27.39M | 33.05M | 38.25M | 48.91M |
| Total Amortization of Deferred Charges | 12.77M | 14.07M | 13.43M | 7.41M | 7.05M |
| Total Other Non-Cash Items | 148.99M | 125.99M | 112.05M | 39.73M | 9.79M |
| Change in Net Operating Assets | -33.13M | 19.00M | -11.88M | -14.56M | -29.07M |
| Cash from Operations | 83.16M | -546.00K | -132.40M | -202.61M | -245.20M |
| Capital Expenditure | -16.26M | -13.46M | -8.19M | -9.40M | -8.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 0.00 | 61.38M |
| Cash from Investing | -16.26M | -13.46M | -8.19M | -9.40M | 52.93M |
| Total Debt Issued | 27.87M | 27.87M | 27.87M | 0.00 | 199.98M |
| Total Debt Repaid | -106.00K | -88.00K | -91.00K | -99.00K | -157.00K |
| Issuance of Common Stock | 536.10M | 532.51M | 532.01M | 2.75M | 1.53M |
| Repurchase of Common Stock | -18.66M | -18.24M | -1.68M | -22.00K | -- |
| Issuance of Preferred Stock | 121.24M | 121.24M | 121.24M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.44M | -1.47M | 3.66M | -1.16M | -1.06M |
| Cash from Financing | 664.99M | 661.82M | 683.00M | 1.47M | 200.29M |
| Foreign Exchange rate Adjustments | 130.00K | 158.00K | 80.00K | -1.00K | -4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 732.01M | 647.97M | 542.49M | -210.54M | 8.02M |